MacroGenics, Inc. (MGNX) — Analyst outlook / Analyst consensus target is. Based on 22 analyst ratings, the consensus is bullish — 12 Buy, 9 Hold, 1 Sell.
The consensus price target is $9.44 (low: $2.00, high: $32.00), representing an upside of 168.2% from the current price $3.52.
Analysts estimate Earnings Per Share (EPS) of $-1.11 and revenue of $0.17B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.07 vs est $-1.11 (beat +3.2%). 2025: actual $-1.18 vs est $-1.09 (missed -7.9%). Analyst accuracy: 95%.
MGNX Stock — 12-Month Price Forecast
$9.44
▲ +168.18% Upside
Average Price Target
Based on 22 Wall Street analysts offering 12-month price targets for MacroGenics, Inc., the average price target is $9.44, with a high forecast of $32.00, and a low forecast of $2.00.
The average price target represents a +168.18% change from the last price of $3.52.
Highest Price Target
$32.00
Average Price Target
$9.44
Lowest Price Target
$2.00
MGNX Analyst Ratings
Buy
Based on 22 analysts giving stock ratings to MacroGenics, Inc. in the past 3 months
EPS Estimates — MGNX
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.07
vs Est –$1.11
▲ 3.3% off
2025
Actual –$1.18
vs Est –$1.09
▼ 7.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — MGNX
90%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.148B
vs Est $0.166B
▼ 12.1% off
2025
Actual $0.150B
vs Est $0.139B
▲ 7.1% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
